About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
D
Current Management of DLBCL From Frontline to Relapsed Disease
By
Dipenkumar Modi
2 Videos
287 views
June 5, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
16:51
Incyte
Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk
Feat.
C. Harrison
Featured Video
37:21
Amgen Sponsorship
New Approval for Frontline Consolidation in Patients with CD19-posit…
Feat.
J. Mccloskey
Related Content
AUTOPLAY
ON
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
16:57
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Lymphoma Highlights"
Feat.
B. D. Cheson
22:11
SOHO Brazil 2024
Has the 1L SoC Truly Changed in Advanced Stage DLBCL?
Feat.
A. Zelenetz
13:07
Moffitt Cancer Center
R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?
Feat.
J. Chavez
22:09
Scripps Health
New Updates in Frontline DLBCL
Feat.
L. Nastoupil
27:47
Indy Hematology Review
Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…
Feat.
S. Smith
35:27
Louisville Hematology Highlights
Updates on Management of DLBCL
Feat.
J. Leonard
04:04
Wojciech Jurczak
Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial
10:04
Tara Graff
How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…
09:18
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…
Feat.
J. Westin
20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Will Immune Therapy Replace Transplant in Hematologic Malignancies?
Feat.
R. Gale
08:01
Georg Lenz
Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC
20:34
UChicago Medicine
Sequencing of Bispecifics With Other Therapies in DLBCL
Feat.
E. Budde
08:23
Total Health
R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment
Feat.
J. Chandler,
B. Randolph,
M. Onciu
35:24
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: Aggressive B-Cell Lymphomas
Feat.
G. Nowakowski
17:07
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Comparative Review of Toxicities and Their…
Feat.
M. Minnema
34:36
MyCancerHaven
Frontline DLBCL Treatment Approaches
Feat.
R. Vij,
H. Cherng
28:33
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
The Truth About Current Consensus Statements on Hematopoietic Cell T…
Feat.
R. Gale
29:26
Massachusetts General Hospital Cancer Center
Practice-Changing Updates in DLBCL and HL
Feat.
J. Erika Haydu
16:34
Jennifer Amengual
Top 5 Lymphoma Abstracts From ASH